General form of registration statement for all companies including face-amount certificate companies

LIQUIDITY (Details Narrative)

v3.21.4
LIQUIDITY (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jan. 07, 2021
Jan. 31, 2020
Sep. 30, 2019
May 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Nov. 05, 2021
Mar. 25, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Cash and cash equivalents         $ 3,180,000     $ 3,180,000   $ 2,772,000 $ 2,321,000    
Accounts receivable, net         6,518,000     6,518,000   8,028,000 10,338,000    
Current assets         12,800,000     12,800,000          
Liabilities, Current         22,800,000     22,800,000          
Net loss         3,561,000 $ 6,234,000   11,214,000 $ 18,308,000 26,451,000 26,740,000    
Net cash used in operating activities               7,501,000 12,395,000 13,979,000 18,957,000    
Cash and cash equivalents         3,180,000     3,180,000   2,772,000 2,321,000    
Total current assets         13,083,000     13,083,000   14,122,000 16,510,000    
Total current liabilities         $ 22,836,000     22,836,000   $ 18,233,000 $ 17,292,000    
Repayment of line of credit               3,000,000        
Sale of common stock                   178,000 97,817    
Debt Instrument, Interest Rate                   8.00%      
Series B Preferred Stock [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Proceeds from public offering   $ 19,200,000                      
Sale of common stock   20,000                      
Equity Distribution Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Proceeds from public offering     $ 3,700,000                    
ATM Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Proceeds from public offering                   $ 700,000      
Sale of common stock                   178,000      
Centers for Medicare & Medicaid Services [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Loans payable           2,100,000 $ 2,100,000   2,100,000        
Department of Health and Human Services [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Loans payable           $ 650,000 650,000   $ 650,000        
Utilization of advance payment against cash payments             $ 2,100,000            
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Proceeds from loans payable       $ 888,000                  
Silicon Valley Bank [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Repayment of line of credit                   $ 3,400,000      
Subsequent Event [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Cash on hand                       $ 2,400,000 $ 3,200,000
Debt Instrument, Interest Rate 8.00%                        
Maturity Date Jun. 30, 2021                        
Subsequent Event [Member] | Secured Promissory Note [Member] | Ampersand 2018 Limited Partnership [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Debt Instrument, Face Amount $ 3,000,000                        
Subsequent Event [Member] | Secured Promissory Note [Member] | 1315 Capital [Member] | Series B Preferred Stock [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Debt Instrument, Face Amount $ 2,000,000